CHRS - upcoming catalyst - breakout ahead ?
Updated
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
This is not a financial advice!
Upcoming catalyst in 2024
A few block buys last months
Short Float 26.86 %
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Key level is 2.5 - needs to get broken.
Keep an eye on 2.85 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 2.15
TP approx. 3.7
Most info on the chart.
Trade carefully!
This is not a financial advice!
Upcoming catalyst in 2024
A few block buys last months
Short Float 26.86 %
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Key level is 2.5 - needs to get broken.
Keep an eye on 2.85 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 2.15
TP approx. 3.7
Most info on the chart.
Trade carefully!
Trade closed: stop reached
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.